Protara Therapeutics (TARA) Operating Leases (2019 - 2026)

Protara Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• In Q1 2026, Operating Leases fell 27.68% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 27.68% YoY), while the FY2025 annual figure was $2.1 million, down 36.98% from the prior year.
• Operating Leases was $3.1 million for Q1 2026 at Protara Therapeutics, up from $2.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $6.2 million in Q1 2022 to a low of $2.1 million in Q4 2025.
• Historically, Operating Leases has averaged $4.4 million across 5 years, with a median of $4.2 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Leases jumped 532.44% in 2022, then slumped 36.98% in 2025.
• A 5-year view of Operating Leases shows it stood at $5.5 million in 2022, then declined by 17.98% to $4.5 million in 2023, then fell by 25.09% to $3.4 million in 2024, then sank by 36.98% to $2.1 million in 2025, then surged by 44.4% to $3.1 million in 2026.
• The last three Operating Leases figures came in at $3.1 million (Q1 2026), $2.1 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.